DE60332842D1 - Antagonisten des nogo-rezeptors - Google Patents
Antagonisten des nogo-rezeptorsInfo
- Publication number
- DE60332842D1 DE60332842D1 DE60332842T DE60332842T DE60332842D1 DE 60332842 D1 DE60332842 D1 DE 60332842D1 DE 60332842 T DE60332842 T DE 60332842T DE 60332842 T DE60332842 T DE 60332842T DE 60332842 D1 DE60332842 D1 DE 60332842D1
- Authority
- DE
- Germany
- Prior art keywords
- nogo receptor
- nogo
- antagonists
- antigen
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40286602P | 2002-08-10 | 2002-08-10 | |
PCT/US2003/025004 WO2004014311A2 (en) | 2002-08-10 | 2003-08-07 | Nogo receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60332842D1 true DE60332842D1 (de) | 2010-07-15 |
Family
ID=31715907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60332842T Expired - Lifetime DE60332842D1 (de) | 2002-08-10 | 2003-08-07 | Antagonisten des nogo-rezeptors |
Country Status (21)
Country | Link |
---|---|
US (2) | US7465705B2 (de) |
JP (3) | JP2005535329A (de) |
KR (1) | KR20050062525A (de) |
CN (1) | CN1681838A (de) |
AT (1) | ATE469913T1 (de) |
AU (1) | AU2003264033A1 (de) |
BR (1) | BR0313331A (de) |
CA (1) | CA2495121A1 (de) |
DE (1) | DE60332842D1 (de) |
DK (1) | DK1534736T3 (de) |
EA (1) | EA200500330A1 (de) |
ES (1) | ES2346868T3 (de) |
IL (2) | IL166659A0 (de) |
IS (1) | IS7677A (de) |
MX (1) | MXPA05001615A (de) |
NO (1) | NO20050685L (de) |
PL (1) | PL375301A1 (de) |
PT (1) | PT1534736E (de) |
RS (2) | RS20050129A (de) |
WO (1) | WO2004014311A2 (de) |
ZA (2) | ZA200501135B (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
DK1325130T3 (da) * | 2000-10-06 | 2010-05-25 | Univ Yale | Nogo-Receptorhomologer |
ATE500842T1 (de) | 2002-05-04 | 2011-03-15 | Acorda Therapeutics Inc | Zusammensetzungen und verfahren zur förderung des neuronalen wachstums |
WO2004014311A2 (en) | 2002-08-10 | 2004-02-19 | Yale University | Nogo receptor antagonists |
WO2004017044A2 (en) * | 2002-08-15 | 2004-02-26 | Acorda Therapeutics, Inc. | Chimeric protein |
ES2537015T3 (es) | 2003-03-19 | 2015-06-01 | Biogen Ma Inc. | Proteína de unión del receptor de NOGO |
KR20060023959A (ko) * | 2003-04-16 | 2006-03-15 | 예일 유니버시티 | 아밀로이드 플라크 관련 상태의 치료용 nogo-수용체길항자 |
EP2460881B1 (de) * | 2003-05-16 | 2017-05-03 | Acorda Therapeutics, Inc. | Proteoglycan-abbauende Mutanten zur Behandlung des ZNS |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
PL1631234T3 (pl) * | 2003-05-16 | 2012-02-29 | Acorda Therapeutics Inc | Kompozycje i sposoby leczenia uszkodzeń OUN |
EA008253B1 (ru) * | 2003-08-07 | 2007-04-27 | Байоджен Айдек Ма Инк. | Антагонисты nogo-рецептора |
US8912144B2 (en) | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
KR20070052237A (ko) * | 2004-01-30 | 2007-05-21 | 비오겐 아이덱 엠에이 아이엔씨. | 노고 수용체 길항제를 사용한, 도파민성 신경 퇴행을수반하는 상태의 치료법 |
ES2411504T3 (es) | 2004-05-18 | 2013-07-05 | Acorda Therapeutics, Inc. | Métodos de purificación de condroitinasa y formulaciones estables de la misma |
BRPI0512500A (pt) | 2004-06-24 | 2008-03-11 | Biogen Idec Inc | tratamento ou condições envolvendo desmielinação |
EP1789070B1 (de) | 2004-08-03 | 2012-10-24 | Biogen Idec MA Inc. | Taj in der neuronalen funktion |
WO2006047049A2 (en) * | 2004-10-01 | 2006-05-04 | Yale University | Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof |
US7893032B2 (en) | 2005-07-07 | 2011-02-22 | Yale University | NgR variants and compositions thereof for suppressing axonal growth inhibition |
JP2009502123A (ja) | 2005-07-08 | 2009-01-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Sp35抗体およびその使用 |
CA2619406A1 (en) * | 2005-08-25 | 2007-03-01 | Biogen Idec Ma Inc. | Nogo receptor polypeptides and polypeptide fragments and uses thereof |
AU2006294755B2 (en) * | 2005-09-26 | 2012-04-19 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
JPWO2007074747A1 (ja) * | 2005-12-26 | 2009-06-04 | 株式会社クラレ | 細胞培養用材料 |
CN103215293B (zh) * | 2006-01-27 | 2015-10-28 | 比奥根Ma公司 | Nogo受体拮抗剂 |
EP2023735A4 (de) * | 2006-05-15 | 2011-05-25 | Biogen Idec Inc | Verwendung von nogo-rezeptor-1(ngr1)-antagonisten zur verbesserung des überlebens von oligodendrozyten |
US8642040B2 (en) | 2006-07-24 | 2014-02-04 | Biogen Idec Ma Inc. | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists |
JP2010502623A (ja) * | 2006-08-31 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Nogoレセプターポリペプチドの末梢投与に関する方法 |
EP2081562B1 (de) | 2006-09-20 | 2016-02-24 | The Board of Regents of The University of Texas System | Verfahren zur abgabe von flüchtigen anästhetika für die regionalanästhesie und/oder schmerzlinderung |
CA3009034C (en) * | 2006-10-10 | 2020-08-18 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
US7906120B2 (en) | 2006-11-21 | 2011-03-15 | Abbott Laboratories | Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) |
WO2009070957A1 (fr) * | 2007-12-05 | 2009-06-11 | Institute Of Genetics And Developmental Biology Chinese Academy Of Sciences | Inhibiteur de l'interaction entre blys et ngr et son utilisation |
EP2244737B1 (de) | 2008-01-22 | 2019-04-10 | The Board of Regents of The University of Texas System | Flüchtige betäubungsmittelzusammensetzungen mit extraktiven lösungsmitteln zur gebietsweisen betäubung und/oder schmerzlinderung |
EP2276500A4 (de) * | 2008-03-13 | 2015-03-04 | Univ Yale | Reaktivierung des axonenwachstums und der axonenerholung bei chronischen rückenmarksverletzungen |
AU2009269099B2 (en) | 2008-07-09 | 2016-03-10 | Biogen Ma Inc. | Compositions comprising antibodies to LINGO or fragments thereof |
EP2323691A2 (de) * | 2008-07-11 | 2011-05-25 | Glaxo Group Limited | Behandlung von amyotrophischer lateralsklerose mit nogo-a-antagonist |
EP2456456A4 (de) * | 2009-07-24 | 2013-11-20 | California Inst Of Techn | Verfahren und zusammensetzungen zur behandlung neuraler schädigungen oder degenerationen |
AU2013246034B2 (en) | 2012-04-09 | 2017-12-07 | Case Western Reserve University | Compositions and methods for inhibiting the activity of LAR family phosphatases |
EP2849787A4 (de) | 2012-05-14 | 2016-06-15 | Biogen Ma Inc | Lingo-2 antagonisten zur behandlung von erkrankungen mit beteiligung von motorneuronen |
KR101685109B1 (ko) * | 2014-12-22 | 2016-12-09 | 경북대학교 산학협력단 | 근육 분화, 재생, 또는 질환 상태와 관련된 노고-에이의 용도 |
WO2016112270A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
CN113527462B (zh) * | 2020-04-22 | 2023-05-23 | 北京大学 | 一种具有镇痛作用的小分子肽及其特异性抗体 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
DK1820858T3 (da) | 1991-03-01 | 2009-11-02 | Dyax Corp | Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
WO2000073452A2 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20020072493A1 (en) | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
EP1088071A4 (de) | 1998-06-16 | 2005-03-02 | Human Genome Sciences Inc | 94 sekretierte menschliche proteine |
CA2347835A1 (en) | 1998-12-01 | 2000-06-08 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
US7041474B2 (en) | 1998-12-30 | 2006-05-09 | Millennium Pharmaceuticals, Inc. | Nucleic acid encoding human tango 509 |
AU784349C (en) | 2000-01-12 | 2006-09-28 | Yale University | Nogo receptor-mediated blockade of axonal growth |
US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
DK1325130T3 (da) | 2000-10-06 | 2010-05-25 | Univ Yale | Nogo-Receptorhomologer |
WO2003018631A2 (en) | 2001-08-27 | 2003-03-06 | Novartis Ag | Nogo receptor homologues and their use |
EP1440091A1 (de) | 2001-10-22 | 2004-07-28 | Novartis AG | Nogo rezeptor homologe und deren verwendung |
US7309485B2 (en) | 2001-12-03 | 2007-12-18 | Children's Medical Center Corporation | Reducing myelin-mediated inhibition of axon regeneration |
US20030113325A1 (en) | 2001-12-03 | 2003-06-19 | Zhigang He | Reducing myelin-mediated inhibition of axon regeneration |
EP1354892A1 (de) | 2002-04-19 | 2003-10-22 | Centre National De La Recherche Scientifique (Cnrs) | Peptide zur Induktion von axonalem Wachstum und ihre Verwendung für die Behandlung neurodegenerativer Erkrankungen |
US7745151B2 (en) | 2002-08-02 | 2010-06-29 | Children's Medical Center Corporation | Methods of determining binding between Nogo receptor and p75 neurotrophin receptor |
WO2004014311A2 (en) | 2002-08-10 | 2004-02-19 | Yale University | Nogo receptor antagonists |
KR20060023959A (ko) * | 2003-04-16 | 2006-03-15 | 예일 유니버시티 | 아밀로이드 플라크 관련 상태의 치료용 nogo-수용체길항자 |
MXPA06001444A (es) | 2003-08-07 | 2006-05-15 | Biogen Idec Inc | Antagonistas del receptor nogo. |
EA008253B1 (ru) | 2003-08-07 | 2007-04-27 | Байоджен Айдек Ма Инк. | Антагонисты nogo-рецептора |
KR20070052237A (ko) * | 2004-01-30 | 2007-05-21 | 비오겐 아이덱 엠에이 아이엔씨. | 노고 수용체 길항제를 사용한, 도파민성 신경 퇴행을수반하는 상태의 치료법 |
JP2010502623A (ja) | 2006-08-31 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Nogoレセプターポリペプチドの末梢投与に関する方法 |
-
2003
- 2003-08-07 WO PCT/US2003/025004 patent/WO2004014311A2/en active Application Filing
- 2003-08-07 AT AT03785123T patent/ATE469913T1/de active
- 2003-08-07 BR BRPI0313331-1A patent/BR0313331A/pt not_active IP Right Cessation
- 2003-08-07 ES ES03785123T patent/ES2346868T3/es not_active Expired - Lifetime
- 2003-08-07 KR KR1020057002176A patent/KR20050062525A/ko not_active Application Discontinuation
- 2003-08-07 AU AU2003264033A patent/AU2003264033A1/en not_active Abandoned
- 2003-08-07 CA CA002495121A patent/CA2495121A1/en not_active Abandoned
- 2003-08-07 DK DK03785123.5T patent/DK1534736T3/da active
- 2003-08-07 MX MXPA05001615A patent/MXPA05001615A/es unknown
- 2003-08-07 CN CNA038214091A patent/CN1681838A/zh active Pending
- 2003-08-07 EA EA200500330A patent/EA200500330A1/ru unknown
- 2003-08-07 PL PL03375301A patent/PL375301A1/xx not_active Application Discontinuation
- 2003-08-07 JP JP2004527960A patent/JP2005535329A/ja active Pending
- 2003-08-07 RS YUP-2005/0129A patent/RS20050129A/sr unknown
- 2003-08-07 PT PT03785123T patent/PT1534736E/pt unknown
- 2003-08-07 DE DE60332842T patent/DE60332842D1/de not_active Expired - Lifetime
-
2004
- 2004-01-30 RS YUP-2006/0089A patent/RS20060089A/sr unknown
-
2005
- 2005-01-28 IS IS7677A patent/IS7677A/is unknown
- 2005-02-02 IL IL16665905A patent/IL166659A0/xx unknown
- 2005-02-08 ZA ZA200501135A patent/ZA200501135B/en unknown
- 2005-02-09 NO NO20050685A patent/NO20050685L/no not_active Application Discontinuation
- 2005-02-10 US US11/055,163 patent/US7465705B2/en not_active Expired - Lifetime
-
2006
- 2006-02-06 IL IL173559A patent/IL173559A0/en unknown
- 2006-03-06 ZA ZA200601909A patent/ZA200601909B/en unknown
-
2008
- 2008-12-15 US US12/335,328 patent/US8030456B2/en not_active Expired - Lifetime
-
2010
- 2010-05-06 JP JP2010106824A patent/JP2010207239A/ja active Pending
-
2011
- 2011-04-07 JP JP2011085613A patent/JP2011173899A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2011173899A (ja) | 2011-09-08 |
ES2346868T3 (es) | 2010-10-21 |
US20050271655A1 (en) | 2005-12-08 |
BR0313331A (pt) | 2007-07-24 |
US20090215691A1 (en) | 2009-08-27 |
EA200500330A1 (ru) | 2006-06-30 |
WO2004014311A3 (en) | 2004-04-29 |
RS20060089A (en) | 2008-08-07 |
US7465705B2 (en) | 2008-12-16 |
MXPA05001615A (es) | 2005-08-19 |
JP2005535329A (ja) | 2005-11-24 |
WO2004014311A2 (en) | 2004-02-19 |
ATE469913T1 (de) | 2010-06-15 |
IL166659A0 (en) | 2006-01-15 |
AU2003264033A1 (en) | 2004-02-25 |
DK1534736T3 (da) | 2010-09-20 |
CA2495121A1 (en) | 2004-02-19 |
US8030456B2 (en) | 2011-10-04 |
KR20050062525A (ko) | 2005-06-23 |
RS20050129A (en) | 2007-06-04 |
PT1534736E (pt) | 2010-09-07 |
CN1681838A (zh) | 2005-10-12 |
PL375301A1 (en) | 2005-11-28 |
IL173559A0 (en) | 2006-07-05 |
IS7677A (is) | 2005-01-28 |
ZA200501135B (en) | 2006-10-25 |
JP2010207239A (ja) | 2010-09-24 |
NO20050685L (no) | 2005-05-10 |
ZA200601909B (en) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60332842D1 (de) | Antagonisten des nogo-rezeptors | |
IS8339A (is) | Mótlyf viðtaka NOGO | |
WO2007089601A8 (en) | Nogo receptor antagonists | |
CY1111097T1 (el) | Πρωτεϊνη δεσμευσης του υποδοχεα nogo | |
WO2002068646A3 (en) | Mammalian cytokines; receptors; related reagents and methods | |
EP1433792A3 (de) | Menschlische-rezeptor Proteine; verwandte Reagenzien und Methoden | |
EA200600376A1 (ru) | Антагонисты nogo-рецептора |